Last reviewed · How we verify
human recombinant erythropoietin
Human recombinant erythropoietin (rHuEPO) binds to erythropoietin receptors on erythroid progenitor cells in bone marrow to stimulate red blood cell production.
Human recombinant erythropoietin (rHuEPO) binds to erythropoietin receptors on erythroid progenitor cells in bone marrow to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients undergoing surgery with anticipated blood loss.
At a glance
| Generic name | human recombinant erythropoietin |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Erythropoietin is a glycoprotein hormone that regulates erythropoiesis by promoting proliferation, differentiation, and maturation of erythroid progenitor cells. By mimicking endogenous EPO, the recombinant form increases hemoglobin and hematocrit levels, improving oxygen-carrying capacity of blood. This is used therapeutically to treat anemia in various clinical contexts.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in cancer patients receiving chemotherapy
- Anemia in patients undergoing surgery with anticipated blood loss
Common side effects
- Hypertension
- Thrombosis (venous and arterial)
- Headache
- Fever
- Injection site reactions
- Pure red cell aplasia (rare)
Key clinical trials
- Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia (PHASE4)
- Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis (PHASE4)
- Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (PHASE4)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Impact of Erythropoietin on Hematological Adaptations and Physical Performance (PHASE4)
- The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion (NA)
- Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: